These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35019268)

  • 21. Engineering Multifunctional Coatings on Nanoparticles Based on Oxidative Coupling Assembly of Polyphenols for Stimuli-Responsive Drug Delivery.
    Liang H; Zhou B; Li J; Liu X; Deng Z; Li B
    J Agric Food Chem; 2018 Jul; 66(26):6897-6905. PubMed ID: 29877704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles.
    Wang M; Zhang J; Yuan Z; Yang W; Wu Q; Gu H
    J Biomed Nanotechnol; 2012 Aug; 8(4):624-32. PubMed ID: 22852472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel thrombolytic agents.
    Verstraete M; Lijnen HR
    Cardiovasc Drugs Ther; 1994 Dec; 8(6):801-11. PubMed ID: 7742258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
    Liu S; Feng X; Jin R; Li G
    Expert Opin Drug Deliv; 2018 Feb; 15(2):173-184. PubMed ID: 28944694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
    Absar S; Kwon YM; Ahsan F
    J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs.
    Hu L; Xu J; Zhang W; Wang J; Fang N; Luo Y; Xu L; Liu J; Zhang Y; Ran H; Guo D; Zhou J
    Int J Nanomedicine; 2022; 17():5229-5246. PubMed ID: 36388875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
    Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Marcos-Contreras OA; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
    Blood; 2010 Jun; 115(25):5241-8. PubMed ID: 20410503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
    Chung TW; Wang SS; Tsai WJ
    Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology of thrombolytic drugs.
    Verstraete M; Collen D
    J Am Coll Cardiol; 1986 Dec; 8(6 Suppl B):33B-40B. PubMed ID: 3097100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An intelligent DNA nanodevice for precision thrombolysis.
    Yin J; Wang S; Wang J; Zhang Y; Fan C; Chao J; Gao Y; Wang L
    Nat Mater; 2024 Jun; 23(6):854-862. PubMed ID: 38448659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis.
    Zhou J; Guo D; Zhang Y; Wu W; Ran H; Wang Z
    ACS Appl Mater Interfaces; 2014 Apr; 6(8):5566-76. PubMed ID: 24693875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-circulating nanoparticles as passive targeting nanocarriers for the treatment of thrombosis.
    Li J; Lu K; Sun S; Peng J; Zhao L
    Nanoscale; 2024 Mar; 16(12):6132-6141. PubMed ID: 38444355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB; Moukhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.